HDAC3 overexpression and colon cancer cell proliferation and differentiation

An immunohistochemical analysis of human colorectal adenocarcinomas showed that cancer cells express widely varying levels of HDAC3. The SW480 colon cancer cell line was found to express high levels of HDAC3 compared to other colon cancer cell lines. p21 was poorly induced in SW480 cells relative to the lower HDAC3‐expressing HT‐29 cells. RNAi‐induced reduction of HDAC3 in SW480 cells increased their constitutive, butyrate‐, TSA‐, and TNF‐α‐induced expression of p21, but did not cause all the gene expression changes induced upon general histone deacetylase (HDAC) inhibition. SW480 cells with lower HDAC3 expression appeared to be poised for gene expression responses with increased histone H4‐K12 acetylation, but not K5, K8, or K16 acetylation. Even though p21 was readily activated in HT29 cells, HDAC3 siRNA nonetheless stimulated p21 expression in these cells to a greater degree than HDAC1 and HDAC2 siRNA. SW480 cells with lower HDAC3 levels displayed an enhanced cell cycle arrest and growth inhibition by butyrate, but without changes in apoptosis or sensitivity to chemotherapeutic agents. As reported for other colon cancer cell lines, butyrate induced the rapid downregulation of the secretory cell differentiation markers mucin 2 and intestinal trefoil factor in SW480 cells. Interestingly, selective HDAC3 inhibition was sufficient to downregulate these genes. Our data support a central role for HDAC3 in regulating the cell proliferation and differentiation of colon cancer cells and suggest a potential mechanism by which colon cancers may become resistant to luminal butyrate. © 2007 Wiley‐Liss, Inc.

[1]  M. Fishman,et al.  Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  E. Sausville,et al.  Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. , 2007, Blood.

[3]  Y. Iwamoto,et al.  The Effects of Histone Deacetylase Inhibitors on the Induction of Differentiation in Chondrosarcoma Cells , 2007, Clinical Cancer Research.

[4]  B. Hinnebusch,et al.  Transcriptional activation of the enterocyte differentiation marker intestinal alkaline phosphatase is associated with changes in the acetylation state of histone H3 at a specific site within its promoter region in vitro , 2003, Journal of Gastrointestinal Surgery.

[5]  Yi Tang,et al.  Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. , 2006, Molecular cell.

[6]  Ronen Marmorstein,et al.  Acetylation of the p53 DNA-binding domain regulates apoptosis induction. , 2006, Molecular cell.

[7]  C. Pérez-Plasencia,et al.  A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer , 2006, PloS one.

[8]  O. O’Connor.  Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma , 2006, British Journal of Cancer.

[9]  Michael Rytting,et al.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.

[10]  E. Noonan,et al.  Circumvention and reactivation of the p53 oncogene checkpoint in mouse colon tumors. , 2006, Biochemical pharmacology.

[11]  P. Houghton,et al.  Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Andrew J. Wilson,et al.  Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer* , 2006, Journal of Biological Chemistry.

[13]  M. Esteller,et al.  New therapeutic targets in cancer: the epigenetic connection , 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[14]  C. Steidl,et al.  The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia , 2006, Cancer.

[15]  L. Schwartz,et al.  Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. , 2006, Clinical lung cancer.

[16]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[17]  M. Duvic,et al.  Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. , 2005, The Journal of investigative dermatology.

[18]  Hiroko Yamashita,et al.  Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast* , 2005, Breast Cancer Research and Treatment.

[19]  M. Dokmanovic,et al.  Prospects: Histone deacetylase inhibitors , 2005, Journal of cellular biochemistry.

[20]  K. Subbaramaiah,et al.  Histone Deacetylase Inhibitors Suppress the Induction of c-Jun and Its Target Genes Including COX-2* , 2005, Journal of Biological Chemistry.

[21]  R. Casadio,et al.  Histone deacetylase 1: a target of 9-hydroxystearic acid in the inhibition of cell growth in human colon cancer Published, JLR Papers in Press, February 16, 2005. DOI 10.1194/jlr.M400424-JLR200 , 2005, Journal of Lipid Research.

[22]  Gesine Hansen,et al.  Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma. , 2005, Lung cancer.

[23]  F. Dequiedt,et al.  Effect of inhibitors of histone deacetylase on the induction of cell differentiation in murine and human erythroleukemia cell lines , 2005, Anti-cancer drugs.

[24]  Li Yu,et al.  [DNA methylation and cancer]. , 2005, Zhonghua nei ke za zhi.

[25]  L. Yin,et al.  Cyclooxygenase-2 Regulation in Colon Cancer Cells , 2005, Journal of Biological Chemistry.

[26]  Suk Woo Nam,et al.  Increased expression of histone deacetylase 2 is found in human gastric cancer , 2005, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[27]  M. Salto‐Tellez,et al.  Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 , 2005, Cell Death and Differentiation.

[28]  S. Voelter-Mahlknecht,et al.  The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. , 2005, International journal of molecular medicine.

[29]  C. Benz,et al.  Clinical development of histone deacetylase inhibitors as anticancer agents. , 2005, Annual review of pharmacology and toxicology.

[30]  Jing Lin,et al.  Trefoil factor family-3 is associated with aggressive behavior of colon cancer cells , 2005, Clinical & Experimental Metastasis.

[31]  Xinxing Wu,et al.  Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells. , 2004, Biochemical and biophysical research communications.

[32]  C. Pilarsky,et al.  Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. , 2004, Neoplasia.

[33]  L. Yin,et al.  The p50-p50 NF-κB complex as a stimulus-specific repressor of gene activation , 2004, Molecular and Cellular Biochemistry.

[34]  M. Gorospe,et al.  Acquisition of Resistance to Butyrate Enhances Survival after Stress and Induces Malignancy of Human Colon Carcinoma Cells , 2004, Cancer Research.

[35]  M. Romero,et al.  The human tumour suppressor gene SLC5A8 expresses a Na+–monocarboxylate cotransporter , 2004, The Journal of physiology.

[36]  Hing Y Leung,et al.  Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer , 2004, The Prostate.

[37]  Ping Zhu,et al.  Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. , 2004, Cancer cell.

[38]  L. Yin,et al.  Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition. , 2004, Biochemical and biophysical research communications.

[39]  L. Yin,et al.  The p50-p50 NF-kappaB complex as a stimulus-specific repressor of gene activation. , 2004, Molecular and cellular biochemistry.

[40]  J. Mariadason,et al.  Repression of MUC2 gene expression by butyrate, a physiological regulator of intestinal cell maturation , 2003, Oncogene.

[41]  M. Lazar,et al.  The N-CoR/Histone Deacetylase 3 Complex Is Required for Repression by Thyroid Hormone Receptor , 2003, Molecular and Cellular Biology.

[42]  C. Plass,et al.  SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Faller,et al.  Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? , 2003, Current cancer drug targets.

[44]  Julia Tischler,et al.  The Tumor Suppressor p53 and Histone Deacetylase 1 Are Antagonistic Regulators of the Cyclin-Dependent Kinase Inhibitor p21/WAF1/CIP1 Gene , 2003, Molecular and Cellular Biology.

[45]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[46]  Peter A. Jones,et al.  Epigenetics in Carcinogenesis and Cancer Prevention , 2003, Annals of the New York Academy of Sciences.

[47]  P. Marks,et al.  Histone deacetylase inhibitors: from target to clinical trials , 2002, Expert opinion on investigational drugs.

[48]  D. O’Carroll,et al.  Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression , 2002, The EMBO journal.

[49]  B. Hinnebusch,et al.  The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. , 2002, The Journal of nutrition.

[50]  Kan Yang,et al.  Colorectal Cancer in Mice Genetically Deficient in the Mucin Muc2 , 2002, Science.

[51]  H. Zoghbi,et al.  Requirement of Math1 for Secretory Cell Lineage Commitment in the Mouse Intestine , 2001, Science.

[52]  H. Kwon,et al.  Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues , 2001, Japanese journal of cancer research : Gann.

[53]  S. Berger,et al.  Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. , 2001, Molecular cell.

[54]  N. Rosen,et al.  The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. , 2001, Cancer research.

[55]  R. Dahiya,et al.  Histone deacetylase and DNA methyltransferase in human prostate cancer. , 2001, Biochemical and biophysical research communications.

[56]  B. Hinnebusch,et al.  Transient vs. prolonged histone hyperacetylation: effects on colon cancer cell growth, differentiation, and apoptosis. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[57]  W. D. Cress,et al.  Histone deacetylases, transcriptional control, and cancer , 2000, Journal of cellular physiology.

[58]  L. Yin,et al.  The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. , 2000, Gastroenterology.

[59]  D. Podolsky.  Mechanisms of regulatory peptide action in the gastrointestinal tract: trefoil peptides. , 2000, Journal of gastroenterology.

[60]  T. Fujioka.  Clarithromycin resistance in Helicobacter pylori: implications for therapy , 2000, Journal of Gastroenterology.

[61]  S. Archer,et al.  Histone acetylation and cancer. , 1999, Current opinion in genetics & development.

[62]  R. Bresalier,et al.  Liver colonization by human colon cancer cells is reduced by antisense inhibition of MUC2 mucin synthesis. , 1999, Gastroenterology.

[63]  R. Whitehead,et al.  Short-chain fatty acids inhibit intestinal trefoil factor gene expression in colon cancer cells. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[64]  A. Eastman,et al.  Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. , 1997, Biochemical pharmacology.

[65]  L. Augenlicht,et al.  Patterns of expression of lineage-specific markers during the in vitro-induced differentiation of HT29 colon carcinoma cells. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[66]  R. Dahiya,et al.  Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. , 1991, The Journal of clinical investigation.

[67]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.